Browse the list of Consortia below to learn more about each CAVD Grant.
Ackerman/Alter: Leveraging Antibody Effector Function Alter: A Generic Approach to Optimizing the Antigenicity of HIV-1 Envelope Immunogens
Baker: Testing the Nearest Neighbor Approach to Active Vaccination for HIV-1 bnAbs Barouch: Novel Vector/Protein Vaccines Barouch: Replicating Adenovirus Vectors Barouch: Therapeutic Efficacy of Potent Broadly Neutralizing mAbs for HIV-1 Eradication Busch: Validation of Existing and Ultra-Sensitive Assays for Qualifying HIV Persistence
Return to top
Ciaramella: mRNA Encoded Abs for HIV Prophylaxis Corey: Support for HVTN 702
Farzan: Preventing HIV-1 transmission with eCD4-Ig Feinberg: IAVI Neutralizing Antibody Consortium
Gallo: FLSC Phase I & II Clinical Trials Gottardo: VISC
Hassell: Vaccine Product Development Center Hassell: Vaccine Product Development Center: GMP Manufacturing, Toxicology, and Clinical Data Management Haynes: B-Cell Lineage Envelope Design Haynes: Centralized Envelope Phase I Study Haynes: MPER-Peptide Liposome Immunogen Testing Haynes: Protein Expression Facility Ho: Engineered Bispecific bNabs for Prevention Hu: Unmasking Conserved Epitopes
Johnson: Single Cell Transcriptional Profiling of Latently-Infected CD4+ T Cells Jolicoeur: Development of a new class of immunogens for raising broadly neutralizing antibodies
Kay: Identifying rAAV Vectors with Enhanced Muscle Transduction via Capsid Evolution Koup: T Cell VIMC Kublin: HVTN:100
Lemon: CAVD Alliance Management Lewis: Ab Specificity & Fc-Mediated Protection Lu: Creating a Better Envelope
Mascola: BNAbs for Passive Immunization Masopust: Vaccination to prevent HIV Infection McElrath: Mucosol Immunology Group McElrath: Durability of HIV-speci c protective Ab responses in human immunology-based experimental medicine trials McMichael: HLA-E restricted CD8 responses induced by CMV vaccines Montefiori: Ab VIMC Moore: Next generation BG505 SOSIP.664-trimer based lineage HIV vaccines
Nolan: Technology Development for HIV Reservoir Characterization Nussenzweig: Clinical Trial of Broadly Neutralizing anti-HIV Antibodies Nussenzweig: Development of optimized broadly neutralizing antibodies for HIV-1 prevention Nussenzweig: Discovery & Characterization of bNAbs
Pantaleo: Generation/Isolation of Novel bnAbs from Lymph Node B cells Pantaleo: Poxvirus-Based Vaccine Development Pantaleo: RepliVax Vaccine Platform Parks: HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues Parks: Live Attenuated VSV-HIV-Env Vaccine Candidate for Evaluation in a Clinical Trial Pettit: Just Biotherapeutics Support for HIV bnAbs Picker: An Attenuated CMV Vector Picker: MHC II and MHC E-Restricted CD8+ T Cells and Control of HIV Pulendran: Protective humoral responses against HIV
Reinherz: HIV clade C MPER immunogens eliciting 10E8-like speci cities Ruprecht: Con rming the Ef cacy of Virosomes Targeting gp41 in Indian Rhesus Macaques
Schmitz/Santra: Second Generation rBCG Immunogens Shattock: DNA Vaccination for HIV Immunogen Discovery Shaw: Novel SHIV Designs to Elicit bnAbs and Guide Iterative Vaccine Development Silvestri: Independent Confirmation of Inactivated AT-2 Treated SIV mac239 and Lactobacillus
Überla: Antibodies without HIV T helper cells
Walker: bNabs after Infection and Immunization Walker: Implications for vaccine design from T and B cell mechanisms of HIV control Ward: Establishment of an Analytics Network to Support Quali ed/Validated Assays Required for Characterization of HIV Env Immunogens